SUCCESS

PARTNERSHIP INTERMEDIARY AGREEMENTS

CONTRACT NUMBER: FA8650-09-3-9400

COMPANY NAME: RevMedX, Inc., Wilsonville, OR

TECHNICAL PROJECT OFFICE:

Technology Transfer Program Office, Wright-Patterson AFB, OH

PUBLISHED: May 2016

LIFE-SAVING WOUND TREATMENT

Revolutionizes Warfighter and Civilian Care

The Air Force has partnered with a private medical company who has developed life-saving technology for the battlefield.

REQUIREMENT

According to Army research, excessive blood loss has reportedly been linked to 90 percent of potentially avoidable deaths from wounds sustained on the battlefield. The Air Force Medical Support Agency is providing technology transition assistance to ReMedX, Inc., to assist with reducing the cost of their wound-treatment invention, XSTAT. This assistance is made possible through the DoD Partnership Intermediary Agreement between the Air Force Research Laboratory and Montana State University/MilTech.



The XSTAT, developed by RevMedX, Inc. (Courtesy photo)

TECHNOLOGY TRANSFER

XSTAT was approved for use on the battlefield by the Federal Drug Administration (FDA) in April 2014.

In late 2014 and early 2015, the USSOCOM were shipped the first production units of XSTAT. And according to a CBS News report, the U.S. Military were the first to use XSTAT in the field to successfully treat a serious leg injury in 2015.

Because of its proven effectiveness in testing, the FDA approved it for civilian use in December 2015, with civilian market availability beginning in February 2016.

"When a product is developed for use in the battlefield, it is generally intended to work in a worst case scenario where advanced care might not be immediately available," said William Maisel, M.D., M.P.H., acting director of the Office of Device Evaluation in the FDAs Center for Devices and Radiological Health. "It is exciting to see this technology transition to help civilian first responders control some severe, life-threatning bleeding while on the trauma scene."

MilTech personnel, along with the Manufacturing Oregon Extension Partnership, a U.S. Department of Commerce NIST MEP Center, are working together with RevMedx personnel in order to lower manufacturing costs. These reductions in costs could potentially create easier access to a life-saving device that has the possibility of saving thousands of lives both on and off the battlefield.

TECHNOLOGY INNOVATION

XSTAT created by RevMedx, Inc. with guidance from the United States Special Operations Command military medics - is designed to control severe bleeding in junctional areas, such as the armpit or groin, where tourniquets or other methods are not successful.


When XSTAT is injected into a wound, it releases 92 sterile, compressed mini sponges that expand up to 10 times their size when in contact with blood or fluid. This potentially life-saving device enables military medics and first responders to dress and pack a wound two three minutes faster than traditional means, such as preparing and applying pressure with both hands to a tourniquet or packing a wound with gauze. This free hand can then tend to a patients vitals and other injuries as the sponges naturally expand and

control bleeding in the wound in a matter of seconds.

The sponges can remain in the patient until they reach definitive care. As with all severe wound requiring surgery, the XSTAT sponges can be removed by a surgeon using standard instruments. All sponges are made visible by the radiopaque markers during a standard X-ray to ensure proper removal prior to closing.

PAYOFF

"We are pleased that XSTAT is now cleared for civilian use, which brings to bear new capabilities to civilian first responders," said Andrew Barofsky, CEO and president of RevMedx Inc. "With this clearance, XSTAT's lifesaving technology can now be used in a variety of settings by trained medical personnel."



The XSTAT, developed by RevMedX, Inc. Inset photo depicts sterile compressed mini sponges. (Courtesy photos)

Linking technology with the mission and marketplace.